This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. -- health coverage from STAT
NIH via AP

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.

LONDON — A U.K. health agency reiterated on Thursday that the limited benefits of a pair of new Alzheimer’s drugs do not justify their high prices, meaning the medicines won’t be made available through the National Health Service.

The decision by the U.K.’s cost-effectiveness watchdog reflects how health authorities in different parts of the world have taken different approaches with the drugs, which are the first to have shown they can slow the progression of the disease but have stoked debate about just how meaningful that progress is for patients and how to weigh their accompanying risks and costs.

advertisement

The drugs — Eli Lilly’s Kisunla (also known as donanemab) and Biogen and Eisai’s Leqembi (lecanemab) — won approval from U.K. regulators last year, with the Medicines and Healthcare products Regulatory Agency finding the benefits of the drugs outweighed the risks for certain patients.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe